Agenus Inc. (AGEN) News
Filter AGEN News Items
AGEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AGEN News Highlights
- For AGEN, its 30 day story count is now at 9.
- Over the past 20 days, the trend for AGEN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- COYA, LUNG and BPMC are the most mentioned tickers in articles about AGEN.
Latest AGEN News From Around the Web
Below are the latest news stories about AGENUS INC that investors may wish to consider to help them evaluate AGEN as an investment opportunity.
Merck (MRK) & Daiichi Sankyo's Lung Cancer ADC Gets Priority TagMerck (MRK) and Daiichi Sankyo's regulatory filing for HER3-DXd gets the FDA's priority review grant for the treatment of adult patients with lung cancer. A final decision is expected on Jun 26, 2024. |
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall StreetThese two biotech stocks could be poised for a trend reversal. |
GSK, Hansoh Ink Deal to Develop Lung Cancer ADC CandidateGSK enters into an exclusive licensing agreement with China-based Hansoh to develop and commercialize the latter's lung cancer candidate, HS-20093. |
Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024LEXINGTON, Mass., December 20, 2023--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that data from an investigator sponsored trial (IST) evaluating botensilimab (BOT, multifunctional CTLA-4 immune activator) in combination with balstilimab (BAL, PD-1 antibody) in neoadjuvant colorectal cancer (CRC) will be presented at the upcoming ASCO-GI Meeting, to be held January 18 – 20, 2024 in San Francisco |
Blueprint (BPMC) Gets EC Nod for Ayvakit Expanded Use, Stock UpBlueprint (BPMC) announces EC approval expanding Ayvakit's indication to include the treatment of adult patients with indolent systemic mastocytosis. The stock gained 5%. |
Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific ProgramLEXINGTON, Mass., December 11, 2023--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced it has triggered the second development milestone payment under its global licensing agreement with Bristol Myers Squibb for BMS-986442, an Fc-enhanced bispecific TIGIT antibody. Agenus will receive a $25 million cash payment from Bristol Myers Squibb with the dosing of the first patient in the phase 2 dose expansion portion of th |
Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus StudyCentury (IPSC) set to begin early-stage study on lead product candidate, CNTY-101, for treatment of systemic lupus erythematosus following IND clearance by FDA. The stock rises 36%. |
Dr. Reddy's (RDY), COYA Ink Deal to Develop COYA 302 for ALSDr. Reddy's (RDY) enters into a licensing agreement with Coya Therapeutics to develop and commercialize the latter's ALS investigational combination therapy, COYA 302. |
Agenus (NASDAQ:AGEN) adds US$36m to market cap in the past 7 days, though investors from three years ago are still down 75%Agenus Inc. ( NASDAQ:AGEN ) shareholders should be happy to see the share price up 13% in the last week. But that is... |
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study (Revised)Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate. |